search
Back to results

Add-on Therapy for Axial Spondyloarthritis

Primary Purpose

Axial Spondyloarthritis

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Add-on Therapy for Axial Spondyloarthritis
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Axial Spondyloarthritis

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of axSpA as assessed by the treating rheumatologist fulfilling the ASAS classification for axial SpA [Rudwaleit 2009]
  • Between 18 and 45 years of age at screening
  • Active disease as defined by an Ankylosing Spondylitis Disease Activity Score (ASDAS) of >2.1 and a CRP value of ≥5 at the screening visit.
  • Ability and willingness to participate to the study and give written informed consent.

Exclusion Criteria:

  • Patients who cannot give written consent or, in the opinion of the investigator, cannot comply to the requirements of the study protocol. Significant comorbidity, including a cardiac, renal, hepatic, neurological, metabolic or any other severe disease, which in the opinion of the investigator may interfere with the study or lead to deleterious effects for the patient.
  • Recent history of (or persistent) infection requiring hospitalization or antibiotic treatment within 4 weeks of baseline.
  • If female, patient should not be pregnant. A urine pregnancy-test will be performed at screening and has to be negative.
  • Initiation of treatment with corticosteroids or DMARDs (synthetic and biologic) within 8 weeks before screening.
  • Initiation of treatment with NSAID within 2 weeks before screening.
  • Variation of the treatment doses within 6 weeks of screening.
  • Intra-articular injection with corticosteroids within 4 weeks prior to screening.
  • Daily doses of systemic corticosteroids exceeding the equivalent of 10 mg prednisolone per day.
  • Use of other drugs and treatments that may affect the evaluation of systemic inflammation as judged by the investigator.
  • Cardiovascular risk factors such as a personal history of cardiovascular disease, familial history of major adverse cardiovascular events (MACE) at age younger than 45 yrs, hypercholesterolemia and stroke.

Sites / Locations

  • Academic Medical Center
  • Ziekenhuis Bernhoven

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Early intervention group

Late intervention group

Arm Description

The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.

This group will receive the same training with a delay of 60-90 days, serving initially as control.

Outcomes

Primary Outcome Measures

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Change in CRP value

Secondary Outcome Measures

Change in circulating cytokines
Change in other serum inflammation biomarkers (ESR, calprotectin)

Full Information

First Posted
March 2, 2016
Last Updated
June 11, 2018
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Bernhoven Hospital, Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT02744014
Brief Title
Add-on Therapy for Axial Spondyloarthritis
Official Title
Evidence-Based Mindset & Physical Therapy for Add-on Treatment of Active Axial Spondyloarthritis: Safety and Efficacy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
April 21, 2016 (Actual)
Primary Completion Date
March 22, 2017 (Actual)
Study Completion Date
December 19, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Bernhoven Hospital, Radboud University Medical Center

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Rationale: Recent investigations suggest that, through certain concentration/meditation techniques, it is possible to modulate autonomic activity. The results of a recent randomized controlled trial investigating the "Wim Hof Method" have shown a direct biological effect on in-vivo cytokine production and are strongly encouraging the clinical evaluation of the technique's efficacy in immune-mediated inflammatory diseases. Objective: To investigate whether an add-on mindset & physical therapy program based on the "Wim Hof Method" can safely and efficaciously be applied in patients with active axial spondyloarthritis. Study design: Prospective open-label randomized controlled trial, safety and efficacy. Study population: Twenty-four patients with active axial spondyloarthritis between 18 and 45 years of age. Intervention: A 30-day training program of add-on mindset and physical therapy for axial spondyloarthritis, using the methodology as designed and instructed by Wim Hof. It involves breathing techniques, training of mindset and concentration, and gradual cold exposure. Main study parameters/endpoints: Safety evaluation of the program is the primary aim of the study. Secondary endpoint is the modulation of serum CRP levels. Exploratory objectives include modulation of clinical disease activity (ASDAS), quality of life (SF-36, EQ-5D), depressive symptoms (HADS), and predictive role of generalized and specific outcome expectancies (EPQ-N, LOT-R, VAS scales).
Detailed Description
Axial spondyloarthritis (axSpA) is a common systemic autoinflammatory disease affecting approximately 7 in 1.000 individuals. Recent investigations suggest that, through certain concentration/meditation techniques, it is possible to modulate autonomic activity. The endotoxemia experiment in an individual (named Wim Hof) who used a self-created concentration/meditation technique is strongly supportive of these findings. The use of his technique - including breathing techniques, training of mindset and concentration, and gradual cold exposure - seemed to evoke a controlled stress response. This response was characterized by sympathetic nervous system activation and subsequent catecholamine/cortisol release, which seemed to attenuate the innate immune response. The remarkable results in the studied individual led to a randomised controlled trial of this technique at the Radboud UMC. Twenty-four healthy individuals were randomised to receive an instruction course of the technique or no instructions at all and subsequently underwent an endotoxemia experiment. The experiment involved the intravenous administration of very low doses of lipopolysaccharide and measuring the in-vivo cytokine response and clinical symptoms. The results of this study have shown a direct biological effect on in-vivo cytokine production and are strongly encouraging the evaluation of the technique's efficacy in clinical practice. The techniques of the Wim Hof Method have been modulated to a scientifically reproducible mindset & physical training program for add-on therapy of axSpA. Specifically, it has been adjusted for potential functional limitations of axSpA. Primary Objective: To investigate whether the add-on mindset & physical therapy program can safely be applied in patients with active axSpA using clinical safety parameters. Secondary Objective: To assess whether the add-on mindset & physical therapy program can modulate objective signs of inflammation in patients with active axSpA using serum biomarkers (e.g. CRP). Exploratory objective: To assess whether the add-on mindset & physical therapy program has an influence on the Ankylosing Spondylitis Disease Activity Score, quality of life, and depressive symptoms (HADS), and to explore the predictive role of generalized and specific outcome expectancies in patients with active axSpA

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Axial Spondyloarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
24 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early intervention group
Arm Type
Experimental
Arm Description
The program starts with a 30-days training course led by course instructor Wim Hof and supervised by the research team. The mindset & physical therapy based on the Wim Hof Method includes breathing techniques, training of mindset and concentration, and gradual cold exposure.
Arm Title
Late intervention group
Arm Type
Other
Arm Description
This group will receive the same training with a delay of 60-90 days, serving initially as control.
Intervention Type
Behavioral
Intervention Name(s)
Add-on Therapy for Axial Spondyloarthritis
Other Intervention Name(s)
Wim Hof Method
Primary Outcome Measure Information:
Title
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Description
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Time Frame
60 days
Title
Change in CRP value
Time Frame
60 days
Secondary Outcome Measure Information:
Title
Change in circulating cytokines
Time Frame
30, 60, 180 days
Title
Change in other serum inflammation biomarkers (ESR, calprotectin)
Time Frame
30, 60, 180 days
Other Pre-specified Outcome Measures:
Title
Change in disease activity as measured by the Ankylosing Spondylitis Disease Activity Score (ASDAS)
Time Frame
30, 60, 180 days
Title
Change in quality of life as measured by the SF-36
Time Frame
30, 60, 180 days
Title
Change in quality of life as measured by the EQ-5D
Time Frame
30, 60, 180 days
Title
Change in depressive symptoms as measured by the Hospital Anxiety Depression Score (HADS).
Time Frame
30, 60, 180 days
Title
Generalized expectations as measured by the Eysenck Personality Questionnaire - Neuroticism scale (EPQ-N)
Time Frame
Baseline
Title
Generalized expectations as measured by the Eysenck Personality Questionnaire - Life Orientation Test-Revised (LOT-R).
Time Frame
Baseline
Title
Specific expectations regarding the effects of the training, measured by VAS scales that are framed to the specific intervention.
Time Frame
Baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of axSpA as assessed by the treating rheumatologist fulfilling the ASAS classification for axial SpA [Rudwaleit 2009] Between 18 and 45 years of age at screening Active disease as defined by an Ankylosing Spondylitis Disease Activity Score (ASDAS) of >2.1 and a CRP value of ≥5 at the screening visit. Ability and willingness to participate to the study and give written informed consent. Exclusion Criteria: Patients who cannot give written consent or, in the opinion of the investigator, cannot comply to the requirements of the study protocol. Significant comorbidity, including a cardiac, renal, hepatic, neurological, metabolic or any other severe disease, which in the opinion of the investigator may interfere with the study or lead to deleterious effects for the patient. Recent history of (or persistent) infection requiring hospitalization or antibiotic treatment within 4 weeks of baseline. If female, patient should not be pregnant. A urine pregnancy-test will be performed at screening and has to be negative. Initiation of treatment with corticosteroids or DMARDs (synthetic and biologic) within 8 weeks before screening. Initiation of treatment with NSAID within 2 weeks before screening. Variation of the treatment doses within 6 weeks of screening. Intra-articular injection with corticosteroids within 4 weeks prior to screening. Daily doses of systemic corticosteroids exceeding the equivalent of 10 mg prednisolone per day. Use of other drugs and treatments that may affect the evaluation of systemic inflammation as judged by the investigator. Cardiovascular risk factors such as a personal history of cardiovascular disease, familial history of major adverse cardiovascular events (MACE) at age younger than 45 yrs, hypercholesterolemia and stroke.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique Baeten, MD PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Academic Medical Center
City
Amsterdam
Country
Netherlands
Facility Name
Ziekenhuis Bernhoven
City
Uden
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
22685240
Citation
Kox M, Stoffels M, Smeekens SP, van Alfen N, Gomes M, Eijsvogels TM, Hopman MT, van der Hoeven JG, Netea MG, Pickkers P. The influence of concentration/meditation on autonomic nervous system activity and the innate immune response: a case study. Psychosom Med. 2012 Jun;74(5):489-94. doi: 10.1097/PSY.0b013e3182583c6d.
Results Reference
background
PubMed Identifier
24799686
Citation
Kox M, van Eijk LT, Zwaag J, van den Wildenberg J, Sweep FC, van der Hoeven JG, Pickkers P. Voluntary activation of the sympathetic nervous system and attenuation of the innate immune response in humans. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7379-84. doi: 10.1073/pnas.1322174111. Epub 2014 May 5.
Results Reference
result
PubMed Identifier
31790484
Citation
Buijze GA, De Jong HMY, Kox M, van de Sande MG, Van Schaardenburg D, Van Vugt RM, Popa CD, Pickkers P, Baeten DLP. An add-on training program involving breathing exercises, cold exposure, and meditation attenuates inflammation and disease activity in axial spondyloarthritis - A proof of concept trial. PLoS One. 2019 Dec 2;14(12):e0225749. doi: 10.1371/journal.pone.0225749. eCollection 2019.
Results Reference
derived

Learn more about this trial

Add-on Therapy for Axial Spondyloarthritis

We'll reach out to this number within 24 hrs